Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Castle Biosciences (Nasdaq: CSTL) will release fourth-quarter and full-year 2025 financial results after market close on Thursday, Feb. 26, 2026.

Rhea-AI Summary

Castle Biosciences (Nasdaq: CSTL) will release fourth-quarter and full-year 2025 financial results after market close on Thursday, Feb. 26, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern the same day with a brief Q&A and a replay available.

Argus Feb 5 session

-7.32% close to close Open Argus

Details

News Market Reaction – CSTL

In the Feb 5 session, CSTL declined 7.32%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.3% in the session following this news. A negative reaction despite this being an ...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite this being an earnings date announcement would contrast with the modestly positive responses to recent operational and clinical updates, including the preliminary FY2025 results that saw a 0.81% move higher. The stock already traded 21.05% below its 52-week high before this release, and insider activity over the past months reflected net selling. Such factors could amplify downside pressure if the forthcoming results or commentary fail to meet expectations formed after the preliminary numbers.

Key Figures

Earnings release date: Feb. 26, 2026 Earnings period end: Dec. 31, 2025 Conference call time: 4:30 p.m. Eastern +2 more

Earnings release date

Feb. 26, 2026

Scheduled Q4 and full-year 2025 results release

Earnings period end

Dec. 31, 2025

Fiscal period for upcoming reported results

Conference call time

4:30 p.m. Eastern

Scheduled time of results conference call

US dial-in number

1 833 470 1428

Phone access to live conference call

Call access code

695618

Access code for the live conference call

Historical Context

5 past events · Latest: Jan 11

5 events

1. Jan 11

   Preliminary 2025 results

   24h Move

   +0.8%

   Preliminary FY2025 revenue above guidance and strong core test growth.

2. Dec 19

   Inducement equity grants

   24h Move

   -0.4%

   RSU inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4).

3. Dec 17

   Clinical study results

   24h Move

   +1.6%

   Large UM study showing DecisionDx-UM + PRAME outperform mutation analysis.

4. Dec 12

   Meta-analysis data

   24h Move

   +1.7%

   Systematic review confirming TissueCypher improves Barrett’s Esophagus risk stratification.

5. Dec 09

   Expert endorsement

   24h Move

   +0.4%

   Expert panel paper recommending DecisionDx-Melanoma as best-practice tool.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details
A live webcast of the conference call can be accessed here: https://events.q4inc.com/attendee/483643109, or via the webcast link on the Investor Relations page of the Company’s website: https://ir.castlebiosciences.com/overview/default.aspx. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.

To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 695618. International dial-in numbers are available here: https://www.netroadshow.com/events/global-numbers?confId=94133; please use the same access code above to join the call.

There will be a brief Question and Answer session following management commentary.

About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X. 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com

Source: Castle Biosciences Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Castle Biosciences (CSTL) release Q4 and full-year 2025 results?

The company will release results after market close on Thursday, Feb. 26, 2026. According to the company, the announcement covers the fourth quarter and year ended Dec. 31, 2025 and will be followed by a management conference call at 4:30 p.m. Eastern.

How can investors access Castle Biosciences (CSTL) Feb. 26, 2026 conference call and webcast?

Investors can join via live webcast or phone using provided links and dial-ins. According to the company, the webcast is on its investor relations site and phone access uses access code 695618; join at least 10 minutes before the 4:30 p.m. Eastern start time.

Will a replay of the Castle Biosciences (CSTL) Feb. 26, 2026 webcast be available after the call?

Yes, a replay will be available following the conclusion of the conference call. According to the company, the replay can be accessed via the same webcast link on its investor relations page for those unable to join live.

What topics will Castle Biosciences management cover on the Feb. 26, 2026 call?

Management will discuss fourth-quarter and full-year 2025 financial results and provide commentary. According to the company, remarks will include management discussion followed by a brief Question and Answer session for investor inquiries.

What international dial-in options exist for Castle Biosciences (CSTL) Feb. 26, 2026 call?

International dial-in numbers are available through the provided global numbers link and use the same access code. According to the company, callers should use access code 695618 and join at least 10 minutes prior to the 4:30 p.m. Eastern start time.